Home › NDC Lookup › RxCUI directory › RxCUI 2361311

Nimodipine 6 MG/ML Oral Solution — RxCUI 2361311

RxNorm drug concept · Semantic clinical drug
RxCUI 2361311 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2361311
Official nameNimodipine 6 MG/ML Oral Solution
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asnimodipine 30 MG per 5 mL Oral Solution; nimodipine 60 MG per 10 mL Oral Solution
FDA products mapped2
Package NDCs mapped4
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Nimodipine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Nimodipine is given specifically after a subarachnoid hemorrhage — that's when an aneurysm in the brain ruptures and bleeds into the space around the brain. After that kind of blee...
  • What exactly is nimodipine being used for in my (or my family member's) care?
  • It's a lot, yes — and there's a real pharmacological reason. Nimodipine is eliminated from the body relatively quickly, so blood levels drop fast between doses. Taking it every 4 h...
  • Why does it have to be taken every 4 hours? That's a lot.
📖 Read our full Nimodipine guide →

🕸️ Concept Web — How Nimodipine 6 MG/ML Oral Solution Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Nimodipine 6 MG/ML Oral Solution RxCUI 2361311

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Nimodipine 7426
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Nymalize 1423768
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Nimodipine Oral Solution 373088
    • Nimodipine Oral Liquid Product 1159234
    • Nimodipine Oral Product 1159235
    • Nimodipine Oral Solution [Nymalize] 1423770
    • Nymalize Oral Liquid Product 1423771
    • Nymalize Oral Product 1423772
    • Oral Solution 316968
    • Oral Liquid Product 1151137
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Nimodipine 6 MG/ML SCDC · 2361310
  • Nimodipine Oral Solution SCDF · 373088
  • Nimodipine Oral Liquid Product SCDG · 1159234
  • Nimodipine Oral Product SCDG · 1159235

Brand-Name Concepts

  • Nimodipine 6 MG/ML Oral Solution [Nymalize] SBD · 2361313
  • Nimodipine 6 MG/ML [Nymalize] SBDC · 2361312
  • Nimodipine Oral Solution [Nymalize] SBDF · 1423770
  • Nymalize Oral Liquid Product SBDG · 1423771
  • Nymalize Oral Product SBDG · 1423772
  • Nymalize BN · 1423768

📦 FDA Products & Package NDCs

2 products · 4 package NDCs
4 package NDCs map to RxCUI 2361311 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
24338-0230-12 12 PACKAGE in 1 CARTON (24338-230-12) / 1 SYRINGE, PLASTIC... Nymalize Azurity Pharmaceuticals, Inc. 2020-05-04
24338-0230-30 12 BLISTER PACK in 1 CARTON (24338-230-30) / 1 SYRINGE, PLA... Nymalize Azurity Pharmaceuticals, Inc. 2024-09-30
24338-0260-08 237 mL in 1 BOTTLE (24338-260-08) Nymalize Azurity Pharmaceuticals, Inc. 2021-07-13
24338-0260-12 12 PACKAGE in 1 CARTON (24338-260-12) / 1 SYRINGE, PLASTIC... Nymalize Azurity Pharmaceuticals, Inc. 2020-05-04
Observed labelers: Azurity Pharmaceuticals, Inc. (4) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.